Breaking News Instant updates and real-time market news.

PTLA

Portola Pharmaceuticals

$30.74

-7.03 (-18.61%)

05:49
08/10/18
08/10
05:49
08/10/18
05:49

Portola Pharmaceuticals downgraded to Underperform at Credit Suisse

  • 25

    Aug

PTLA Portola Pharmaceuticals
$30.74

-7.03 (-18.61%)

05/07/18
SBSH
05/07/18
NO CHANGE
Target $64
SBSH
Buy
Portola Pharmaceuticals price target raised to $64 from $58 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Portola Pharmaceuticals to $64 following the FDA approval of Andexxa. The analyst keeps a Buy rating on the shares.
05/07/18
OPCO
05/07/18
NO CHANGE
Target $80
OPCO
Outperform
Portola Pharmaceuticals price target raised to $80 from $67 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Portola Pharmaceuticals to $80 from $67 after AndexXa received FDA approval as the first and only antidote indicated for patients treated with rivaroxaban and apixaban when reversal is needed in the case of life-threatening or uncontrolled bleeding. The analyst believes potential drivers of upside include AndexXa likely expanding factor Xa use and label extensions, U.S. approval of Gen2 manufacturing to expand capacity, European CHMP opinion in Q4 and cerdulatinib data at ASCO. Olson reiterates an Outperform rating on the shares.
05/07/18
MSCO
05/07/18
NO CHANGE
Target $46
MSCO
Equal Weight
Portola price target raised to $46 from $31 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Portola Pharmaceuticals to $46 following the FDA approval of AndexXa, calling it a significant positive. However, he maintains an Equal Weight rating on the shares, as he expects the stock to trade with the market given the limited launch will not allow investors to gauge true demand until 2019.
06/14/18
SBSH
06/14/18
NO CHANGE
SBSH
Buy
Portola not planning sale despite CEO transition, says Citi
Citi analyst Yigal Nochomovitz asked Portola Pharmaceuticals if the CEO transition means the company is potentially up for sale. Management emphasized that the CEO transition should not be interpreted as meaning they are planning to sell the company, Nochomovitz tells investors in a research note. He points out that management reiterated they are working towards advancing the company commercially. With two approved drugs in thrombosis, Portola views itself as well positioned to attract new talent to continue to build its sales force, Nochomovitz writes after speaking to the company. He keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

WEX

Wex

$176.23

5.88 (3.45%)

13:33
02/22/19
02/22
13:33
02/22/19
13:33
Earnings
Wex sees 2019 adjusted EPS $8.80-$9.20, consensus $8.94 »

Sees 2019 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

WEX

Wex

$176.23

5.88 (3.45%)

13:32
02/22/19
02/22
13:32
02/22/19
13:32
Earnings
Wex reported preliminary 2018 adjusted EPS $8.18, consensus $8.18 »

Reported preliminary 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

WEX

Wex

$176.24

5.89 (3.46%)

13:29
02/22/19
02/22
13:29
02/22/19
13:29
Hot Stocks
Wex delays earnings on up to $70M Brazilian subsidiary discrepancy »

Wex announced earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

WEX

Wex

$176.53

6.18 (3.63%)

13:26
02/22/19
02/22
13:26
02/22/19
13:26
Periodicals
Wex CEO tells Bloomberg business 'incredibly healthy' despite Brazil issue »

WEX's overall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

XRX

Xerox

13:20
02/22/19
02/22
13:20
02/22/19
13:20
Downgrade
Xerox rating change  »

Xerox downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$89.55

0.75 (0.84%)

13:20
02/22/19
02/22
13:20
02/22/19
13:20
Downgrade
United Continental rating change  »

United Continental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.89

1.46 (0.53%)

13:20
02/22/19
02/22
13:20
02/22/19
13:20
Periodicals
U.S, China disusing late March summit between Xi and Trump, CNBC reports »

U.S. and China are…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.89

1.46 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKX

Skechers

$33.90

0.29 (0.86%)

13:20
02/22/19
02/22
13:20
02/22/19
13:20
Downgrade
Skechers rating change  »

Skechers downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

DXCM

DexCom

$139.14

-7.14 (-4.88%)

13:17
02/22/19
02/22
13:17
02/22/19
13:17
Hot Stocks
DexCom receives Health Canada approval for G6 CGM System »

Dexcom announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
02/22/19
02/22
13:17
02/22/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
02/22/19
02/22
13:16
02/22/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$19.90

0.33 (1.69%)

13:15
02/22/19
02/22
13:15
02/22/19
13:15
Options
Pure Storage put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 28

    Feb

  • 13

    Mar

13:15
02/22/19
02/22
13:15
02/22/19
13:15
General news
Breaking General news story  »

Philadelphia Federal…

13:15
02/22/19
02/22
13:15
02/22/19
13:15
General news
Breaking General news story  »

US Federal Reserve Bank…

13:15
02/22/19
02/22
13:15
02/22/19
13:15
General news
Breaking General news story  »

St. Louis Federal Reserve…

CGC

Canopy Growth

$44.32

-0.67 (-1.49%)

13:14
02/22/19
02/22
13:14
02/22/19
13:14
Hot Stocks
Canopy reverses decline after CEO talks asset possibilities with Bloomberg »

Shares of Canopy Growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHGE

Baker Hughes

$26.29

0.01 (0.04%)

13:03
02/22/19
02/22
13:03
02/22/19
13:03
Hot Stocks
Baker Hughes reports U.S. rig count down 4 to 1,047 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 22

    May

  • 28

    May

EFX

Equifax

$110.23

-0.28 (-0.25%)

13:00
02/22/19
02/22
13:00
02/22/19
13:00
Hot Stocks
Equifax says U.S. regulators seek damages related to 2017 breach »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

BILI

Bilibili

$19.48

1.34 (7.39%)

13:00
02/22/19
02/22
13:00
02/22/19
13:00
Options
Bullish option flow in Bilibili as shares rally 7% ahead of earnings »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

VALE

Vale

$12.45

0.43 (3.58%)

12:57
02/22/19
02/22
12:57
02/22/19
12:57
Periodicals
Federal prosecutors in Brazil seek arrest of senior Vale exec, Reuters reports »

Federal prosecutors in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$34.99

-13.2 (-27.39%)

, K

Kellogg

$56.53

-1.8 (-3.09%)

12:57
02/22/19
02/22
12:57
02/22/19
12:57
Periodicals
Prescience Point sees Kellogg following Kraft Heinz with dividend cut »

Short seller Prescience…

KHC

Kraft Heinz

$34.99

-13.2 (-27.39%)

K

Kellogg

$56.53

-1.8 (-3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 03

    Mar

SNAP

Snap

$9.74

0.35 (3.73%)

12:50
02/22/19
02/22
12:50
02/22/19
12:50
Options
Snap calls active as shares see strength »

Snap calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

UBNK

United Financial

$16.11

0.02 (0.12%)

12:49
02/22/19
02/22
12:49
02/22/19
12:49
Hot Stocks
FJ Capital reports 6.47% passive stake in United Financial »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$7.49

-1.47 (-16.41%)

12:48
02/22/19
02/22
12:48
02/22/19
12:48
Hot Stocks
Karyopharm drops 40% after FDA posts Selinexor meeting briefing docs »

Shares of Karyopharm are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

HK

Halcon Resources

$1.67

-0.12 (-6.70%)

12:47
02/22/19
02/22
12:47
02/22/19
12:47
Hot Stocks
Fir Tree comments on Halcon CEO departure, renews call for sale of company »

Fir Tree Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.